Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (4040)	6/6/2001 2:26:38 PM
From: Michael Young	Respond to of 52153

True enough. It may be fairer to say that Niaspan flushing is manageable enough to keep good patient compliance. My father claims he has never had any Niaspan problems. MIKE

To: rkrw who wrote (4040)	6/6/2001 2:46:36 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

There are safety issues with immediate-release niacin that would be magnified in a statin combo. So I don't see the OTC niacin as much of a threat, particularly if they had an effective sales force. It's on just about every formulary (lot cheaper than statins...), and so there isn't much incentive for people to go with an OTC product. It probably does serve to put a cap on their pricing though. (It's real cheap as drugs go). They do have some minor patent protection: Kos Pharmaceuticals, Inc. (Nasdaq: KOSP) announced today that it has received a method-of-use patent (U.S. # 6,080,428) for the once-at-night dosing of niacin to safely treat cholesterol disorders. A second niacin patent, covering the dosing regimen and additional safety and formulation claims, also has been allowed and is expected to issue shortly. These two patents reserve for Kos, until 2017, the use of niacin administered once daily at night for cholesterol therapy, whether alone or in combination with other compounds, effectively creating an exclusive franchise both for the Company's currently marketed Niaspan(R) product and for its next-generation product, Nicostatin(TM). Anyone want a patent for lunchtime dosing? <g> Peter